New Delhi, Sep 21 (IANS) The Indian Cancer Genome Atlas (ICGA) on Saturday launched India’s first comprehensive cancer multi-omics data portal to boost research and treatment against the deadly disease, affecting millions of people globally.
The platform provides open access to clinically correlated data from Indian cancer patients, aimed at transforming cancer research and treatment for Indian populations.
Cancer treatments in India have always been based on Western data sets. However, cancers in Indian patients can differ significantly at the molecular level.
This new open-access portal represents a monumental step in revolutionising cancer research and will enable personalised treatment for Indian patients.
“The multi-omics portal is the first in India to offer data that includes DNA, RNA, and protein profiles of breast cancer patients, integrated with clinical outcomes,” said the non-profit.
Currently, the platform consists of data from 50 breast cancer patients, with plans to expand to over 500 patients in the coming year. This data is freely accessible to the global research community under India’s PRIDE guidelines, which promote ethical sharing and collaboration in cancer research.
The platform is based on the internationally recognised cBioPortal platform and ensures seamless integration with global cancer research efforts.
“We have made an excellent start with this groundbreaking multi-omics cancer portal. Cancer touches all of us, and the need for more effective, personalised treatments — specially tailored to the unique genetic and environmental factors in India — is urgent,” said Dr. Anand Deshpande, Non-Executive Director at ICGA.
“This portal will empower researchers with crucial data to advance customised cancer research for better treatment outcomes. I encourage everyone to contribute and support this vital cause, helping us accelerate progress in the fight against cancer,” he added.
A recent report from Apollo Hospitals dubbed India the “cancer capital of the world”.
About 12 lakh new cancer cases and 9.3 lakh deaths were registered in India in 2019. The report by Lancet showed India is the second highest contributor to the disease burden in Asia.
The number increased to 13.9 lakh in 2020, which then rose to 14.2 lakh and 14.6 lakh in the years 2021 and 2022, respectively. With increasing age, pollution, poor diet, and unhealthy lifestyles, the numbers will soar significantly.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
